{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+2%2C+Placebo+Group&page=7", "query": { "intervention": "Part 2, Placebo Group", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 280, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+2%2C+Placebo+Group&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+2%2C+Placebo+Group&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T05:02:35.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02700919", "title": "Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "BCT197", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mereo BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 282, "start_date": "2016-08-01", "completion_date": "2017-11-28", "has_results": true, "last_update_posted_date": "2020-11-30", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 3, "location_summary": "Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin", "locations": [ { "city": "Michigan City", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02700919" }, { "nct_id": "NCT00656110", "title": "Neuroma Injections to Treat Restless Legs Syndrome - RCT", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Restless Legs Syndrome" ], "interventions": [ { "name": "equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml", "type": "DRUG" }, { "name": "Normal saline - 1ml", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lowcountry Infectious Diseases", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2008-04", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2009-03-10", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00656110" }, { "nct_id": "NCT04988308", "title": "A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Bermekimab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2021-10-12", "completion_date": "2022-11-23", "has_results": true, "last_update_posted_date": "2023-11-13", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04988308" }, { "nct_id": "NCT02333331", "title": "Dose Range Finding Study of Bimagrumab in Sarcopenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcopenia" ], "interventions": [ { "name": "bimagrumab", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 217, "start_date": "2014-12-09", "completion_date": "2018-06-28", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 17, "location_summary": "Little Rock, Arkansas • Cypress, California • La Jolla, California + 14 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cypress", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02333331" }, { "nct_id": "NCT06707142", "title": "A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Participants" ], "interventions": [ { "name": "TBD11", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gates Medical Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 124, "start_date": "2024-12-05", "completion_date": "2026-02-27", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06707142" }, { "nct_id": "NCT00752050", "title": "Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glabellar Rhytides", "Frown Lines Between the Eyebrows" ], "interventions": [ { "name": "Mentor Purified Toxin Botulinum Toxin Type A", "type": "DRUG" }, { "name": "Preservative-free Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mentor Worldwide, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 699, "start_date": "2007-11", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2011-09-12", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 1, "location_summary": "Santa Barbara, California", "locations": [ { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752050" }, { "nct_id": "NCT02734862", "title": "CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Candidemia", "Mycoses", "Fungal Infection", "Fungemia", "Invasive Candidiasis" ], "interventions": [ { "name": "CD101", "type": "DRUG" }, { "name": "Caspofungin", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" }, { "name": "oral placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 207, "start_date": "2016-07-26", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Davis, California • Miami, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Davis", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02734862" }, { "nct_id": "NCT02978326", "title": "A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Postpartum Depression" ], "interventions": [ { "name": "SAGE-217 15/20 mg Oral Solution", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "SAGE 217 30 mg Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 276, "start_date": "2017-01-04", "completion_date": "2018-12-11", "has_results": true, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Wildomar", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02978326" }, { "nct_id": "NCT02066792", "title": "Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Social Anxiety Disorder" ], "interventions": [ { "name": "D-Cycloserine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cognitive Behavioral Therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Jasper A. Smits", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 152, "start_date": "2014-04", "completion_date": "2018-07-01", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Austin, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02066792" }, { "nct_id": "NCT02877134", "title": "Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "JNJ-64304500", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 388, "start_date": "2016-08-25", "completion_date": "2022-01-24", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-15T05:02:35.481Z", "location_count": 37, "location_summary": "Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more", "locations": [ { "city": "Lone Tree", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02877134" } ] }